Company Profile

Jaguar Animal Health, Inc. is an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses. Canaleviaâ„¢ is Jaguar's lead prescription drug product candidate, intended for the treatment of various forms of diarrhea in dogs. Equileviaâ„¢ (formerly referred to as SB-300) is Jaguar's prescription drug product candidate for the treatment of gastrointestinal ulcers in horses. Canaleviaâ„¢ and Equileviaâ„¢ contain ingredients isolated and purified from the Croton lechleri tree, which is sustainably harvested. Neonormâ„¢ Calf and Neonormâ„¢ Foal are the Company's lead non-prescription products. Neonormâ„¢ is a standardized botanical extract derived from the Croton lechleri tree. Canaleviaâ„¢ and Neonormâ„¢ are distinct products that act at the same last step in a physiological pathway generally present in mammals. Jaguar has nine active investigational new animal drug applications, or INADs, filed with the FDA and intends to develop species-specific formulations of Neonormâ„¢ in six additional target species, formulations of Equileviaâ„¢ in horses, and Canaleviaâ„¢ for cats and dogs.